MedTrace Logo

Impact of RYALTRIS® Nasal Spray on Patients' Reported Outcomes

NCT05129306 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2022-04-07

No results posted yet for this study

Summary

A real world evidence study that aims to understand the impact of RYALTRIS® nasal spray in patients with Allergic Rhinitis over a 28-day period.

Conditions

  • Allergic Rhinitis

Interventions

OTHER

Observational

In this observational study, participants with moderate to severe Allergic Rhinitis who were initiated on Ryaltris® nasal spray by their healthcare professional will complete an online survey before commencement of treatment and then at days 1, 7, and 14 from treatment initiation. Survey completion at day 28 after treatment initiation will be optional for participants based on ongoing use of RYALTRIS®.

Sponsors & Collaborators

  • Seqirus Limited

    collaborator UNKNOWN

  • Glenmark Pharmaceuticals

    collaborator UNKNOWN

  • Community and Patient Preference Research Pty Ltd

    lead INDUSTRY

Principal Investigators

  • Simon Fifer, PhD · Community and Patient Preference Research Pty Ltd

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-17
Primary Completion
2022-03-14
Completion
2022-03-14

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05129306 on ClinicalTrials.gov